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Abstract
Objective-: Insulin resistance (IR) is an important risk factor for type 2 Diabetes Mellitus (DM2)
and cardiovascular disease (CVD). Metabolic Syndrome (MS) is a clustering of metabolic alterations
associated to IR; however, there is no international consensus for defining its diagnosis. Our
objective was to evaluate the prevalence and characteristics of MS identified by the ATP III and IDF
criteria in adults from Talca city.
Research and methods-: We studied 1007 individuals, aged 18–74, and residents from Talca. MS
subjects were defined according to ATP III (three altered factors) and IDF criteria (patients with
waist circumference >80/90 cm (W/M) and two others altered factors).
Results-: The prevalence of metabolic syndrome according to the IDF and ATP III criteria was
36.4% and 29.5%, respectively after adjustment for age and sex. The agreement for both criteria
was 89%. The prevalence in men was higher than in women for both MS definitions, although not
significant. MS probability increased with age, and the highest risk was in the 57–68 age group (ATP-
MS) and 53–72 age group (IDF-MS). Hypertension, high triglycerides and abdominal obesity are the
most frequent alterations in MS.
Conclusion-:  MS prevalence in adults was higher when diagnosed with IDF than with ATP
criterion; in both, age is directly related with the MS presence. The MS subjects showed higher
levels of blood pressure, waist circumference and plasma triglycerides. Considering our results, it
is worrisome that one third of our population has a high risk of developing DM2 and CVD in the
future.
Introduction
Insulin resistance (IR) is an important risk factor for type
2 Diabetes Mellitus (DM2) and cardiovascular disease
(CVD) [1-3]. It is characterized by a decrease in biologic
insulin action, so plasmatic insulin levels are higher to
maintain normal glucose plasma levels [4]. Several studies
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support the relationship between insulin resistance (IR)
and CVD [5-8]. However, insulin sensitivity measurement
is complex and expensive, so the model proposed by
Mathews et al. [9] that estimates the degree of IR at base-
line by the homeostasis model assessment (HOMA-IR)
has acquired importance. Metabolic Syndrome (MS) is a
clustering of metabolic alterations associated to IR, but
conceptual differences exist between the currently availa-
ble definitions [10,11]. Reaven [2] was the first to describe
this combination as a syndrome that he called IR syn-
drome or simply "X Syndrome"; later the World Health
Organization (WHO) named it Metabolic Syndrome. This
definition based the diagnosis of MS on the presence of
hypertension, hypertriglyceridemia, low HDL cholesterol
(HDLc), hyperglycemia and/or, hyperinsulinism, but also
added the waist/hip ratio and urinary albumin excretion
as components of this syndrome [12,13].
The progressive increase in obesity, CVD and MS preva-
lence motivated the National Cholesterol Education Pro-
gram (NCEP) on its third panel: Treatment of High Blood
Cholesterol in Adults (ATP III) [14], to propose clinical cri-
teria to define MS by the presence of at least three altered
factors: High blood pressure (BP), hypertriglyceridemia,
low HDLc, high plasmatic glucose and abdominal obes-
ity. This definition was simple, so various prospective
studies adopted the definition and determined its relation
to CVD, but later the NCEP criteria were criticized because
the identification of those affected is strongly influenced
by ethnicity [15-17]. The thresholds were selected based
on evidence from studies in Caucasian populations and
variability among ethnic groups was not taken into
account since waist circumference and body composition
are different in Asian and Hispanic populations [18-20].
The International Diabetes Federation (IDF) proposed a
new definition for MS [21] that is based on the impor-
tance of abdominal obesity as a condition that must be
present in all subjects with the syndrome, and that the
threshold for waist circumferences must be defined in
each country for its own ethnic groups [22]. In Latin-
American populations, since there are no epidemiologic
studies to define the best waist circumference cut-off
points, it was suggested to be considering the same values
as those of south-Asiatic populations who consider
altered waists being over 80 cm in women and 90 cm in
men. Consequently IDF-MS is defined as abdominal
obesity with the presence of two altered factors, as is ATP-
MS. IDF considered abnormal glucose over 100 mg/dl as
was suggested by the American Diabetes Association
(ADA) [23]. Furthermore, the American Association of
Clinical Endocrinologist (AACE) and the American Heart
Association (AHA) agree on the lower glucose level but
have decided to keep the ATP III diagnosis criteria [24] for
MS.
Although there is controversy about the diagnosis, most
of the authors agree that the presence of MS is associated
with a higher risk of developing DM2 and CVD [25-27]
and they include as important factors for the diagnosis,
the alterations in waist circumference, BP, HDLc, triglycer-
ides and glucose levels.
Due to the high incidence of MS in Chile and in Talca
[28], we decided to study the prevalence and characteris-
tics of MS using the IDF and ATP diagnosis criteria and the
relative importance of their individual components.
Research design and methods
We studied 1007 subjects, aged 18 to 74 years old, resi-
dents of Talca, Chile [29]. The study group was selected
from a probabilistic polietapic sampling scheme. In the
first step, blocks were numbered according census district,
then with a simple randomization 361 blocks were
selected in the city. In the second step, by a systematic
selection procedure, 8 houses per block were selected and
a trained surveyor selected one subject per house by using
the Kish table [30]. Anthropometric and arterial blood
pressure measurements and blood extractions (for glucose
and lipids) were performed at the Clinical Laboratory of
the Health Sciences School at the Universidad de Talca.
Informed consent was signed by all participant subjects.
The protocol was approved by the ethic committee from
Universidad de Talca and Health Service of Maule, Chile.
The diagnosis criteria used for MS were: a) According to
ATP definition (ATP-MS): three or more of the following
factors: 1) Blood pressure: Systolic ≥ 130 mmHg and/or
diastolic ≥ 85 mmHg and/or subjects who received anti
hypertension drug therapy. 2) Triglycerides: ≥ 150 mg/dl;
3) HDL cholesterol: <40 in men and <50 mg/dl in
women; 4) Plasmatic glucose: ≥ 100 mg/dl, and/or sub-
jects who received anti diabetic drug therapy and 5) Waist
circumference: >102 cm in men and >88 cm in women;
and b) MS according to IDF definition (IDF-MS): Waist
circumference over 90 cm in men and over 80 cm in
women, and the presence of any two altered factors
described above for the ATP criteria.
Statistical analysis
MS prevalence was adjusted according to population dis-
tribution by age and sex according to the 2002 national
census. Means differences between sexes were evaluated
using the Student t-test. Agreement analysis was per-
formed to compare diagnosis criteria with the Mc-Nemar
test and the Kappa statistic test [30]. We adjusted a gener-
alized additive model to evaluate the probability of MS
associated with age under both criteria [31]. We used SAS
9.1.3, software for statistical analysis.Nutrition Journal 2008, 7:14 http://www.nutritionj.com/content/7/1/14
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Results
From the 1007 total subjects, 37.5% presented over-
weight,32.6% obesity, and 41.1% abdominal obesity;
37% had high BP and 26.3% impaired fasting glucose;
and 40.1% had high triglycerides and 21.5% low HDLc.
The anthropometric and biochemistry characteristics by
sex are shown in Table 1. There was no difference in age
and BMI between men and women; however, all the other
parameters were significantly different.
Prevalence of metabolic syndrome
449 (44.6%) subjects presented MS including the ATP
and/or IDF criteria and 75% of them presented MS
according to both criteria. The average age in these
patients was 51.6 ± 11.8 years for patients diagnosed with
ATP criteria and 51.1 ± 12.0 years for individuals diag-
nosed with IDF. The IDF criteria detected more prevalence
of MS than the ATP criteria (Table 2). 357 subjects
(35.5%) were diagnosed as having MS by ATP criteria and
430 patients (42.7%) by IDF criteria. After adjusting for
age and sex, the prevalence of MS according to IDF was
36.4%, which is significantly higher than the prevalence
found by ATP criteria (29.5%) (p = 0.001). Men presented
a tendency for higher MS prevalence, however, these dif-
ferences were not significant (IDF: 39.0% y 34.0%, p =
0.138; ATP: 30.1% y 29.0%, p = 0.786 in men and
women, respectively). The MS risk for age according to
both criteria is shown in Figure 1. MS probability
increased with age, with the highest risk in the 57–68 age
group (ATP-MS) and 53–72 age group (IDF-MS).
In relation to the distribution of the involved factors, we
observed a similar behavior for ATP and IDF MS that is
expected if we consider that there is an important overlap
among the subjects. If we consider ATP vs. IDF, respec-
tively, high blood pressure (83.8% vs. 77.9%); high trig-
lycerides (74.5% vs. 71.6%) and increased waist
circumference (77.9% vs. 100%) were the major compo-
nents found in subjects with MS, independent of the crite-
ria, followed by hyperglycemia (57.7% vs. 51.4%) and
low HDLc, in both men and women (65.6% vs. 61.9%).
Analysis of the concordance from the different syndrome 
status
When we compare the concordance between both diag-
nostic criteria, the Kappa statistic was 0.77 (95% CI 0.73–
0.81), which suggests a good concordance between the
ATP and the IDF diagnosis for MS. We evaluated the dis-
crepancies in the diagnosis and we observed that the IDF
criteria were more likely to diagnose MS as positive as the
ATP criteria (McNemar test: p < 0.001); 9.1% was diag-
nosed with MS using only IDF, and 1.9% was diagnosed
with MS using only ATP criteria.
Discussion
MS presents a high prevalence in the world and in Chile
[25]. In Latin America there are no other published stud-
ies about MS-IDF with the present waist circumference
cut-off points. Park et al. [32] reported a MS-IDF preva-
lence of 13.5% in men and 15.0% in women in the
Korean population, which is remarkably lower than our
prevalence. Boehm et al. [33] found in studies that older
German people (over 55 years old) showed an important
discordance between both diagnosis criteria: in females a
prevalence of 24% with ATP and 46% with IDF and in
males 28% y 57%, respectively. These differ from our
results that found 75% of concordance for both criteria.
The MS prevalence varies depending on the diagnosis cri-
teria; most are higher with IDF than ATP. Also there is
marked disagreement if we consider the geographic
regions and the ethnic origin, so it would be interesting to
compare our findings with similar populations. However,
we did find two studies of Hispanic populations that are
similar to ours. The Chilean National Health Report
showed that MS was present in 27% of the Maule Region
population, which is similar to the 31% reported for
Americans of Hispanic origin [34]. Both studies used ATP
criteria with glycaemia over 110 mg/dl so the criterion was
not exactly the same as in our study where we used 100
mg/dl as the cut-off point. In spite of this, those results are
similar to the 29% found by our group for ATP-SM.
Other groups have reported important differences in the
prevalence of MS by sex. The Americans did not find dif-
ferences in the NCEP study [34], neither did the Philip-
pines [35], the Spanish in the Canary Islands [36] or the
Koreans [32]. We did not find significant difference by
sex, even though with IDF criteria women present a ten-
dency to show a higher prevalence. Nevertheless, there are
many populations where there are marked differences by
sex, as for the Iranians in the Teheran study; where a prev-
alence of 42% in women and 24% in men was found [37].
Table 1: Characteristics of studied subjects by sex (n = 1007).
Men Women
Mean ± SD Mean ± SD
N3 3 9 6 6 8
Age (years) 44.3 ± 15.1 45.6 ± 13.5
BMI (kg/mt2) 28.3 ± 4.5 28.5 ± 5.8
Waist circumference (cm) 96.3 ± 12.0 89.2 ± 13.0*
Systolic blood pressure (mmHg) 133.8 ± 19.6 124.5 ± 20.8*
Diastolic blood pressure (mmHg) 80.7 ± 12.4 75.8 ± 11.0*
Triglycerides (mg/dl) 190.4 ± 175.2 147.6 ± 95.4*
HDLc (mg/dl) 45.8 ± 12.3 55.0 ± 15.3*
Glucose (mg/dl) 100.2 ± 29.2 93.7 ± 24.1*
BMI: body mass index; HDLc: HDL cholesterol
*Student t-test: p < 0.05Nutrition Journal 2008, 7:14 http://www.nutritionj.com/content/7/1/14
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Similarly, the Indian study reported 46.5% in women and
36.4% in men [38]. A Lithuania study, using IDF criteria,
found a prevalence of 28.1% in men and 16.6% in
women [39], similar to the San Antonio Heart Study that
had 28.9% in men, and 20.8% in women [6]. Also, a sim-
ilar prevalence was reported by Magi in Italians [40], but
they found greater ATP-MS in women (27%) than in men
(22%).
The most frequent individual factor is high blood pressure
in most of the populations studied; for instance, Ameri-
cans [8], Lithuanians [40], Koreans [32] and Philippines
[35], and also in our MS subjects for both sexes. Table 3
shows a comparison of prevalence of MS according ATP
criteria in different areas. Talca results show a higher prev-
alence compared to that found in other Chilean studies
and in other countries. Bustos et al., [41] showed 10.1%
of MS prevalence in a semirural population of Chile
(Limache) and Brasil (Riberao Preto), 7.6%. These popu-
lations had an average age of 24 years and the prevalence
found is similar to the data presented in Figure 1, which
shows results by age.
Finally, we believe that the evidence remains controversial
concerning the definition of MS and its relationship to
CVD [42,43]. Consequently, finding the best diagnostic
Table 2: Characteristics of subjects with Metabolic Syndrome ATP and IDF definition
Male Female
ATP IDF ATP IDF
N 117 155 240 275
BMI (kg/m2) 31.0 ± 4.3 30.5 ± 3.9 32.5 ± 5.8 31.9 ± 5.6
Waist circumference (cm) 104.5 ± 11.2 103.0 ± 9.9 99.2 ± 11.0 97.7 ± 10.9
Systolic blood pressure (mmHg) 143.7 ± 18.9 141.1 ± 19.3 136.5 ± 21.8 135.3 ± 22.0
Diastolic blood pressure (mmHg) 86.8 ± 12.0 85.9 ± 12.4 81.5 ± 11.1 80.8 ± 11.1
Triglycerides (mg/dl) 282.1 ± 250.9 260.9 ± 227.8 201.3 ± 115.1 201.9 ± 117.2
HDLc (mg/dl) 40.7 ± 11.4 40.4 ± 10.3 46.7 ± 11.6 47.5 ± 12.5
Glucose (mg/dl) 115.6 ± 39.1 111.9 ± 38.3 106.0 ± 33.1 104.5 ± 32.3
BMI: body mass index; HDLc: HDL cholesterol
Data are means ± SD unless other was indicated.
Prevalence of Metabolic Syndrome according ATP and IDF definition by age Figure 1
Prevalence of Metabolic Syndrome according ATP and IDF definition by age.
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criteria and their significance require more study. On
other hand, the healthy waist circumference cut-off point
is a problem for different ethnic groups and populations.
In this article, we used the IDF-MS classification for waist
circumference based on the limit proposed for Latin
America, which was homologated from the Asian popula-
tion. However, we believe that the Chilean physical con-
stitution is more similar to the European than Asian
population. Thus, it is necessary to establish our own
tables based on local population studies.
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